We could not find any results for:
Make sure your spelling is correct or try broadening your search.
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Top Brokers
Investor discussions surrounding Oxford Biomedica Plc (OXB) this week highlighted varying sentiments regarding the company's stock prospects and potential takeover interest. A participant expressed skepticism about a £7-9 bid being adequate, while another reported selling shares, suggesting fluctuating trading dynamics. Notably, discussions revealed apprehensions regarding OXB's defenses against opportunistic bids, with sentiments emerging that the company's current share price may suggest vulnerability. This concern was echoed when one investor observed, “I have to say that the impression I took from the AGM was that there was a feeling of potential vulnerability to an opportunistic bid.”
In terms of financial outlook, speculation on OXB’s revenues for the upcoming year indicated a prediction of approximately £180 million, pointing towards a year of record revenue. Quotes such as "the behavior of the company hasn't appeared to be helping their share price" encapsulated the frustration of investors amid perceived underperformance and challenges in the market context. Despite these concerns, discussions about the company's strategic position and future prospects remained active, with hopes for a more stable and significantly valued future. Several participants highlighted the potential impact of OXB's reintegration into indices like the FT250 as a catalyst for renewed investor interest. Overall, while some investors remain hopeful about OXB's future growth, underlying worries continue to cloud investor sentiment regarding its valuation and the competitive pharmaceutical market.
Show more
Oxford Biomedica Plc (LSE: OXB) has reported several key developments in recent weeks, highlighting its ongoing strategic initiatives and governance changes. Notably, as of December 2, 2024, the company's total issued share capital stands at 105,938,933 ordinary shares, which shareholders can use for determining notification obligations under the FCA's Disclosure Guidance. Additionally, new executive compensation arrangements were announced, including the grant of long-term incentive plan (LTIP) awards to key management, scaled back by 20% as part of best practice governance.
The company is also expanding its engagement in the biopharmaceutical community, with a forthcoming free webinar scheduled for December 9, 2024, focused on the use of advanced robotics in accelerating the development of viral vector products. This reflects OXB's commitment to innovation in cell and gene therapy manufacturing. Furthermore, the Board has undergone changes with the appointment of Colin Bond as a new Non-Executive Director, effective January 1, 2025, as part of planned succession efforts. These developments demonstrate OXB's proactive approach to governance and its focus on enhancing operational capabilities within the competitive biopharmaceutical landscape.
Show more
Just like Mr. President I suspect, and certainly myself. |
I really really wish I was a good day trader and had the b*lls to sell the tops hold cash and nip in on the dips...an exciting adrenaline ride compared to LTBH....just not brave enough sadly.... |
At least we have bounced off the 400 level. |
#9021 Actually a Carpenter, small black creature. What does that imply. |
Public sector Good - Private sector Bad |
It's a strange old world gutterhead. |
I promised I wouldn't do any more on politics for a while, but bear with me. |
Yes,equities could bounce back,the weakness is partly technical,resulting from the paranoia that this Government has managed to inject into the investment climate as it flays about looking to fine tune its tax grab.However,i doubt this administration will do anything to advance the cause of UK equity ownership,a market which has been well down the international league table over the last quarter century. Labour seem to have a belief that the public sector is in someway more inherently worthy and capable of orchestrating beneficial changes than a freewheeling private sector.They might be right yet this government reminds me constantly of the allegorical book Animal Farm.Selling gilts is one thing but attracting overseas investors to UK equities might be difficult especially if Trump is pedalling unbridled capitalism in the US.Meanwhile the attraction of smaller UK equities could be significantly diminished by AIM losing the IHT concession which it needs given that markets woeful performance.However, |
My monitor list on ADVFN is just a sea of red at the moment (oh happy day) but surely some anecdotal evidence that this is a market-wide selloff today? |
You'll have worked out that I'm pretty sold on the idea SJ, but having spent my working life in something totally unrelated that doesn't really carry a lot of weight. |
"If their fund rules had them cumulatively holding 800k shares which they previously had to sell, won't they now have to buy them back?"That would be my understanding.Tracke |
Perhaps Dom, but tbh I'm more interested today in reading what anybody with market experience might think of post 9007. |
Perhaps more likely the wily Indians have worked out that £50m is a worthwhile price to be able to say they CAN distribute production, but make as much as they can in India until someone complains (if they do complain). |
There's a high level aim to make it locally in Africa. Have to be careful what you say about that else diplomatic incidents happen, but I think that might be more the dream than the reality. |
I think k if we say Serum = Malaria vaccine, then there is a stated aim for a geographic diversity in production. |
Not sure if we understand the Serum deal correctly They have paid for the option to use OXB facilities at any time in the next ten years This is an insurance policy for them if there is production disruption in IndiaUnless such a scenario happens why start production here at I presume at a more costly rate ? |
The recent good run is probably prompting some selling to realise capital gains pre budget.It wouldn't be a great surprise if Reeves imposed capital gains changes to take effect immediately ie from midnight Oct 30th. |
Dom, |
Disappointing. But I guess after a full week of increases some are going to take something off the table. |
Cousin, |
Interesting what happens before and after 14.30pm (assuming NYC is still 5 hours behind. Apologies! Already open! |
Nothing goes up in a straight line, unless the newsflow is frequent and wholeheartedly positive. Consolidation is probably not a bad thing. |
Type | Ordinary Share |
Share ISIN | GB00BDFBVT43 |
Sector | Medicinal Chems,botanicl Pds |
Bid Price | 425.00 |
Offer Price | 427.00 |
Open | 430.00 |
Shares Traded | 258,355 |
Last Trade | 16:35:13 |
Low - High | 411.50 - 430.50 |
Turnover | 89.54M |
Profit | -184.16M |
EPS - Basic | -1.7479 |
PE Ratio | -2.43 |
Market Cap | 453.05M |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions